The FDA has approved an expanded label for GlaxoSmithKline’s new Trelegy Ellipta inhaler, allowing it to be used in a broader population of patients with chronic obstructive pulmonary disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback